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Abstract
Background: The molecular basis and characteristics of familial non-medullary thyroid cancer are poorly understood. In this
study, we performed microRNA (miRNA) profiling of familial and sporadic papillary thyroid cancer tumor samples.
Methodology/Principal Findings: Genome wide miRNA profiling of sporadic and familial papillary thyroid cancer was
performed. Differentially expressed miRNAs were validated by quantitative RT-PCR. Ectopic expression of miR-886-3p in
thyroid cancer lines was performed to identify pathways targeted by the miRNA, as well as, to determine its effect on tumor
cell biology. We found four differentially expressed miRNAs between familial and sporadic papillary thyroid cancer tumor
samples. MiR-886-3p and miR-20a were validated to be differentially expressed by 3- and 4-fold, respectively. Pathway
analysis of genome-wide expression data on cells overexpressing miR-886-3p and target prediction analysis showed genes
involved in DNA replication and focal adhesion pathways were regulated by miR-886-3p. Overexpression of miR-886-3p in
thyroid cancer cell lines significantly inhibited cellular proliferation, the number and size of spheroids and cellular migration.
Additionally, overexpression of miR-886-3p increased the number of cells in S phase.
Conclusions/Significance: Our findings for the first time suggest that miR-886-3p plays an important role in thyroid cancer
tumor cell biology and regulates genes involved in DNA replication and focal adhesion. Thus, miR-886-3p may play a role in
the initiation and or progression of papillary thyroid cancer.
Citation: Xiong Y, Zhang L, Holloway AK, Wu X, Su L, et al. (2011) MiR-886-3p Regulates Cell Proliferation and Migration, and Is Dysregulated in Familial Non-
Medullary Thyroid Cancer. PLoS ONE 6(10): e24717. doi:10.1371/journal.pone.0024717
Editor: Marian Ludgate, Cardiff University, United Kingdom
Received June 10, 2011; Accepted August 17, 2011; Published October 5, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This study was funded by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kebebewe@mail.nih.gov
Introduction
Thyroid cancer is one of the fastest growing cancer diagnoses in
the United States with more than 44,000 new cases estimated to
occur in 2011 [1]. Familial non-medullary thyroid cancer
(FNMTC) may occur as a minor component of familial cancer
syndromes (Gardner’s, Cowden’s disease, Carney complex type 1,
Werner syndrome, McCune-Albright syndrome) or as the
predominate feature [2]. Most cases of FNMTC are papillary
thyroid cancer and have an autosomal dominant pattern of
inheritance with incomplete penetrance. FNMTC accounts for up
to 8% of all thyroid cancer cases [2,3,4,5,6]. In the familial cancer
syndromes mentioned above, patients present with distinct
extrathyroidal lesions and the susceptibility genes responsible for
these syndromes are known. However, the majority (.95%) of
FNMTC cases occur as isolated familial nonmedullary thyroid
cancer cases for which the susceptibility gene(s) is unknown.
FNMTC is defined as when two or more first-degree relatives
are affected with non-medullary thyroid cancer. The genetic basis
of FNMTC is poorly understood. In linkage studies, several groups
have identified chromosomal loci associated with FNMTC: 1q21,
2q21, 6q22, 8p23.1-p22, and 19p13.2 [7],[8], [9],[10], [11],
[12],[13]. Mutation analysis has shown that kindreds with
FNMTC do not have germ line mutations in BRAF, RAS, and
RET/PTC genes that are commonly mutated somatically in
thyroid cancers of follicular cell origin [2]. Furthermore, analysis
of somatic mutations (BRAF, RAS, and RET/PTC) in sporadic and
familial papillary thyroid cancer tumor samples showed no
difference in the rate and type of mutations in these histologies
[2,6,14]. Thus, it is unknown if the molecular profile of sporadic
versus familial thyroid cancer is different. Moreover, it is also
unknown if there is a molecular basis for the earlier age of onset
and more aggressive disease behavior observed in FNMTC
compared to sporadic disease [6,15,16].
MicroRNAs (miRNAs) are small (,21-nucleotide-long) non-
coding RNAs, which regulate gene expression and play a
significant role in many biological processes, including tumori-
genesis [1–2]. A specific miRNA may function either as an
oncogene or as a tumor suppressor by regulating the expression of
target oncogene(s) and tumor suppressor gene(s), respectively. In
most cases, miRNAs bind to 39-untranslated regions (39-UTRs) of
target mRNAs, leading to mRNA degradation or repression of
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polymorphism in pre-miR-146a has been reported to inhibit
mature miRNA expression and increase the risk of developing
papillary thyroid cancer [17]. To our knowledge, no studies have
been performed comparing the miRNA profiles of familial and
sporadic cancers in general and specifically for thyroid cancer.
In this study, we performed miRNA profiling of familial and
sporadic papillary thyroid cancer tumor samples. We found that
miR-886-3p was downregulated in papillary thyroid cancer as
compared to normal and differentially expressed in familial
papillary thyroid cancer as compared to sporadic papillary thyroid
cancer. Pathway analysis of genome-wide expression data on cells
overexpressing miR-886-3p and target prediction analysis showed
genes involved in the DNA replication and focal adhesion pathway
were regulated by miR-886-3p. Indeed, overexpression of miR-
886-3p in thyroid cancer cell lines significantly inhibited cellular
proliferation, the number and size of spheroids and migration.
Materials and Methods
Thyroid tissue samples
Thyroid tissue samples were snap frozen in liquid nitrogen at
the time of thyroidectomy. The National Cancer Institute review
board approved this research protocol after informed written
consent was obtained from all participants. All tissue samples
underwent additional histological review by an endocrine
pathologist to confirm the diagnosis and identify samples with
greater than 80% tumor cells. We used 28 conventional papillary
thyroid cancer tumor samples (21 sporadic, 7 familial) and 10
normal thyroid tissue samples for the miRNA array profiling. A
family history questionnaire was used to ascertain if tumors should
be categorized as sporadic or familial. FNMTC was defined when
2 or more first degree relatives were affected with thyroid cancer of
follicular cell origin. Cases of thyroid cancer were confirmed in
affected family members. All of the FNMTC tumor samples were
from different families. In 5 of 7 tumor samples of FNMTC there
were three first degree relatives affected and in 2 of 7 there were
two first degree relatives affected. The tumor samples were
matched for age (+/22 years), gender and TNM stage of cancer
(at a 3:1 ratio of sporadic-to-familial cases).
MiRNA microarray
A total of 28 microarrays (Exiqon
TM) were run comparing both
familial and sporadic papillary thyroid cancers to a pool of normal
thyroid tissue. The log2 ratio of the Cy5 to Cy3 intensity signals was
calculated for each miRNA on every array (with no background
subtraction) and the data was normalized by print tip loess
normalization [18,19]. Since individual miRNAs were represented
by four probes on the array, the median normalized log2 ratio of the
replicate probes (for those with more than one unflagged probe) was
used as the value for the miRNA. The summarized log2 ratios for
each experiment were then used in moderated t-statistics and p-
value calculation using the limma package in R/Bioconductor
[20,21]with adjustmentforfalsediscoveryrate usingtheBenjamini-
Hochberg method [22]. MiRNA microarray data, which is
MIAME compliant, has been deposited in the GEO database
(http://www.ncbi.nlm.nih.gov/geo).
Cell lines and culture conditions
Human thyroid cancer cell lines FTC-133 (follicular thyroid
cancer) and TPC-1 (papillary thyroid cancer) were maintained in
Dulbecco’s Modified Eagle Medium (DMEM) with 4,500 mg/L D-
Figure 1. MiRNA expression in thyroid tissue. A) Comparison of differentially expressed miRNAs in sporadic and familial papillary thyroid cancer
compared to normal thyroid tissue. The sporadic circle indicates this group’s comparison to normal thyroid tissue, the familial circle indicates this
group’s comparison to normal thyroid tissue, and the familial-sporadic circle indicates comparison between familial and sporadic tumors. B) Relative
percent miRNA expression difference between familial and sporadic tumors normalized to normal tissue samples. * p value,0.05.
doi:10.1371/journal.pone.0024717.g001
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ed with 10% serum, thyroid-stimulating hormone (TSH) (10 mU/
mL), penicillin (10,000 U/mL), streptomycin (10,000 U/mL),
Fungizone (250 mg/mL) and insulin (10 (mg/mL) in a standard
humidified incubator at 37uCi na5 %C O 2 and 95% O2
atmosphere.Both celllines are established and authenticated thyroid
cancer cell lines [23,24,25,26]. The TPC-1 cell line was provided by
Dr. Nabuo Satoh (Japan) and FTC-133 cell line was provided by Dr.
Peter Goretzki (Germany). Serum free media (DMEM-F12 media)
supplemented with 4 hormones (insulin [10 mg/mL], somatostatin
[10 ng/mL], transferrin [5 mg/mL], and hydrocortisone [0.36 ng/
mL]) was used for the functional studies.
MiRNA Transfection
Mature miRNA precursor (pre-miR-886-3p, Applied Biosys-
tems, Foster City, CA) was transfected into cells using Lipofecta-
mine RNAiMAX (Invitrogen, Carlsbad, CA) following the
manufacturer’s instructions. A random sequence pre-miR (pre-
miR-Negative Control) (Applied Biosystems) was used as negative
control (miR-NC).
RNA Isolation and Quantitative real-time RT-PCR
Total RNA was extracted by using TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. TaqMan MiRNA
Assays (Applied Biosystems) were used to measure miRNA
expression level. Total RNA was reverse transcribed with a
miRNA-specific primer, followed by real-time PCR with TaqMan
probes. U6 was used as the endogenous control. The relative
amount of mRNAs was determined using TaqMan Assay (Applied
Biosystems) on an ABI 7900 HT system, using human GAPDH as
an endogenous control. The DD Ct method was used for
calculating expression levels.
Proliferation assay
Cell proliferation was determined using CyQUANT Cell
Proliferation Assay (Invitrogen) according to the manufacturer’s
protocol. The fluorescence intensity was measured using a
fluorescence microplate reader (Molecular Devices, Sunnyvale,
CA).
Migration assay
The migratory ability of thyroid cancer cells was assessed by the
scratch wound assay in cells grown in monolayer. Approximately
150,000 cells were transfected with pre-miR-886-3p (25 nM) or
miR-NC (25 nM) then plated in 6-well plates and allowed to
attach and grow for 44 hours. Thereafter, three vertical wounds
were made with a sterile 10 ml pipette tip and a horizontal line was
made across the three lines to allow observation of cells at the same
point. The cells were inspected every 6 hours and measurements
taken up to 22 hours from the initial wound.
Genome-wide mRNA expression microarray
TPC-1 cells were transfected with pre-miR-886-3p and pre-miR-
NC. Seventy-two hours after transfection, cells were washed three
times with PBS. Total RNA was prepared from triplicate cell
cultures using the RNeasy (Qiagen, Valencia, CA) kit according to
the manufacturer’s instruction. RNA quality was ensured, before
labeling, using the Agilent RNA 6000 Nano kit and the Bioanalyzer
2100.One hundredfiftyng oftotal RNAwasused to performcDNA
reverse transcription, synthesis, amplification, fragmentation and
terminal labeling with the GeneChip WT Sense Target Labeling
and Control Reagents (Affymetrix, Santa Clara, CA). Approximate-
ly 25 ng/mL of cDNA was hybridized to the Affymetrix Human
Gene 1.0 ST Array GeneChip. The arrays were washed and stained
using the fluidics protocol FS450_0007 procedure on an Affymetrix
Fluidics Station 450. The probe intensities were scanned by the
GeneChip Scanner 3000. The raw data was normalized and
analyzed using Partek Genomic Suite (Partek Inc., St Louis, MO,
USA). Analysis of variance was used to determine those probe sets
significantly different between the two groups. The gene list was
filtered with a fold-change cutoff of 2. This resulted inoutput of gene
list with genes that have significant differential expression at
P#0.001 and 2-fold or more differences. Pathway analysis was
performed using the DAVID bioinformatics resources.
Cell cycle flow cytometry analysis
The effects of miR-886-3p overexpression on cell cycle progression
were assessed using propidium iodide flow cytometry. Briefly, TPC-1
and FTC-133 cells were transfected with pre-miR-886-3p or pre-
miR-NCfor72 hoursto120 hours.ThecellswerewashedwithPBS,
harvested, and fixed in 70% ethanol. Then the cells were treated with
(500 U/mL) DNase-free RNase and stained with propidium iodide.
Cell samples were analyzed on a FACSCalibur (BD Biosciences, San
Figure 2. Validation of dysregulated miRNAs in sporadic versus
familial papillary thyroid cancer by quantitative RT-PCR. MiR-
20a was 4-fold and miR-886-3p was 3-fold higher in familial papillary
thyroid cancer as compared to sporadic (p=0.025 for miR-20a, p=0.028
for miR-886-3p, p=0.37 for miR-195, p=0.46 for miR-29c). Values are
average expression plus and minus the standard error of mean. The Y
axis represents the ratio of miRNA and U6 RNA using 2
2DDCt method,
and the lowest value of the sample was set to 1.0.
doi:10.1371/journal.pone.0024717.g002
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using ModFitLT software (Topsham, ME).
Apoptosis flow cytometry analysis
The effects of miR-886-3p overexpression on cell death were
assessed by Annexin V- FITC and propidium iodide flow cytometry
using ApoAlert Annexin V kit (Clontech, Mountain View, CA).
TPC-1and FTC-133 cells weretransfected withpre-miR-886-3por
pre-miR-NC for 72 hours to 120 hours. The cells were harvested
andstained with Annexin V-FITCand propidiumiodideaccording
to the manufacturer’s protocol. Cell samples were analyzed on a
FACSCalibur, and apoptotic fractions were determined.
Luciferase Reporter Assay
The 1160 base pair 39-UTR of CDC6 was cloned into the empty
luciferase reporter vector pEZX-MT01 (GeneCopoeia, Rockville,
MD), generating a wild-type CDC6 UTR luciferase reporter
construct (pEZX-WT-UTR). Mutations in the 39-UTR of CDC6
were designed for the first four nucleotides (CACC to GTGG) or
the last three nucleotides (CGC to GCG) of the 7-mer seed region
of the putative binding site of miR-886-3p, generating two mutants
termed as pEZX-Mut-UTR-01 and pEZX-Mut-UTR-02, respec-
tively. All constructs were sequence-verified by DNA sequencing.
For the dual luciferase assay, TPC-1 cells were plated in triplicate
into 12-well plates and co-transfected with 0.25 mg of the reporter
construct and 15 pmol of pre-miR-886-3p or pre-miR-NC by
using Lipofectamine 2000 (Invitrogen). At 24 hours, the cells were
lysed and assayed for both firefly and renilla luciferase using Luc-
Pair
TM miR Luciferase Assay Kit (GeneCopoeia, Rockville, MD)
on a SpectraMax M5e microplate reader (Molecular Device,
Sunnyvale, CA) according to the manufacturers’ instructions.
Data Analysis
Data is presented as the mean 6 standard error of the mean. To
determine statistical significance, the Mann-Whitney U test, t test
and analysis of variance were used, as appropriate. A p-value of
less than 0.05 was considered statistically significant. All
experiments were repeated at least three times.
Results
MiRNA profiling of sporadic and familial papillary thyroid
cancer
We compared the miRNA expression profile of familial and
sporadic papillary thyroid cancer tumor samples using whole-
genome miRNA microarray analysis. The samples were matched
based on the age and gender of the patients, and the TNM tumor
stage. MiRNA expression in tumor samples was compared to
Figure 3. Work flow of integrated genomic analysis of miR-886-3p target genes and pathways.
doi:10.1371/journal.pone.0024717.g003
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sporadic and 135 miRNAs in familial papillary thyroid cancer
which were dysregulated compared to normal thyroid tissue
samples (Figure 1A)( p ,0.05). One hundred nine of the
dysregulated miRNAs were unique to sporadic, 13 were unique
to familial, and four miRNAs were significantly differentially
expressed between sporadic and familial papillary thyroid cancer
(Figure 1A and 1B). Two of the four miRNAs were validated to
be significantly differentially expressed between familial and
sporadic papillary thyroid cancer by quantitative real time RT-
PCR (Figure 2). Both miR-20a and miR-886-3p were also
significantly downregulated in sporadic papillary thyroid cancer
compared to normal thyroid tissue (p=0.032 and p=0.0032,
respectively) (Figure 1B).
Target genes and pathways of MiR-886-3p in thyroid
cancer cells
Given the function of miR-886-3p in tumor cell biology is
unknown, we were first interested in determining the target gene(s)
and pathway(s) that may be regulated by miR-886-3p. We used
two approaches to determine miR-886-3p targets: miRNA target
prediction and genome-wide mRNA expression analysis in cells
overexpressing miR-886-3p (Figure 3). We found 730 predicted
target genes for miR-866-3p using target prediction databases
(miRanda, miRBase, Target ScanS). By performing KEGG
pathway analysis on the mRNAs dysregulated in miR-886-3p less
under expressed cells, we found genes involved in the DNA
replication and focal adhesion pathways were misexpressed upon
miR-886-3p overexpression in thyroid cancer cell lines. Integra-
Figure 4. Validation of 4 target genes of miR-886-3p by quantitative RT-PCR. Transfection of pre-miR-886-3p significantly decreased the
mRNA levels of four target genes (CDC6, PIP5K1C, PXN, ZYX)i nA) TPC-1 cell line and B) FTC-133 cell line (*p,0.05; ** p,0.01). The Y axis represents
the ratio of the specific target gene and GAPDH using 2
-DDCt method, and the value of the miR-NC group was set at 1.0 to allow comparison of fold
differences among different cell lines and genes.
doi:10.1371/journal.pone.0024717.g004
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e24717Figure 5. Western blot analysis of CDC6 protein expression with pre-miR-886-3p overexpression in TPC-1 cells. A) Representative
western blot image of CDC6 protein expression at 72 hours after transfection with pre-miR-886-3p as compared to negative control (miR-NC). B) Band
densitometry quantification of CDC6 protein expression. The software ImageJ (Maryland, USA) was used for densitometric analysis of western blots.
doi:10.1371/journal.pone.0024717.g005
Figure 6. Analysis of miR-886-3p effect on 39-UTR of CDC6.A ) pEZX-WT-UTR vector with both Renilla luciferase (hRLuc) was used as an internal
control and firefly luciferase (hLuc) was upstream of the 39-UTR construct. B) Putative binding site of miR-886-3p on the CDC6 39 UTR along with the
mutations in the predicted seed region. C) Left figure shows luciferase activity of pEZX-WT-UTR in TPC-1 cells when co-transfected with pre-miR-886-3p or
pre-miR-NC, p,0.05. Middle and right figures showluciferase activity of pEZX-Mut-UTR-01 and pEZX-Mut-UTR-02 in TPC-1 cells when co-transfected with pre-
miR-886-3p or pre-miR-NC, respectively. All luciferase measurements were made in triplicates and readings were performed at 24 hours post-transfection.
doi:10.1371/journal.pone.0024717.g006
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common between the analyses. These genes are therefore
predicted to be miR-886-3p targets.
To further address this hypothesis, we selected four of these
genes for validation upon miR-886-3p overexpression. We found
significant downregulation of all four genes upon miR-886-3p
overexpression by quantitative RT-PCR (Figure 4). Of these
genes, we were particularly interested in CDC6 since this gene
encodes a potent regulator of DNA replication and oncogenesis
[27]. Interestingly, western blot analysis showed downregulation of
CDC6 protein expression within 72 hours of miR-886-3p overex-
pression (Figure 5). To further assess if CDC6 is a direct target of
miR-886-3p regulation, transfection of the 39UTR CDC6 wild type
vector in thyroid cancer cells with miR-886-3p overexpression
showed significant downregulation of luciferase activity suggesting
that CDC6 was a direct target of miR-886-3p (Figure 6).
Mutations in the predicted seed region for miR-886-3p in the
39UTR of CDC6 abolished this effect, further suggesting that miR-
886-3p directly regulates CDC6 expression (Figure 6).
MiR-886-3p regulates cell cycle and proliferation, and
spheroid formation and migration
Because we found miR-886-3p regulates genes involved in DNA
replication and focal adhesion pathways, we were interested in
determining the role of miR-886-3p on cell cycle and cellular
proliferation, as well as, spheroid formation and migration. We first
determined the basal expression of miR-886-3p in four well-
characterized and authenticated thyroid cancer cell lines and found
that FTC-133 and TPC-1 had highest and lowest level of miR-886-
3p expression, respectively (Figure 7A). We used these cells lines to
analyze the effect of miR-886-3p on cell proliferation. Overexpres-
sion of miR-886-3p significantly inhibited cell proliferation by 79%
in FTC-133 cells at 144 hours (p,0.001) and 77% in TPC-1 cells at
120 hours (p,0.001) as compared to pre-miR-NC (Figure 7B).
Given the profound effect of miR-886-3p overexpression on
cellular proliferation, we wanted to next explore the mechanism of
miR-886-3p-mediated growth inhibition. We, thus, performed
flow cytometry and Annexin V assays to determine the effect of
miR-886-3p on cell cycle progression and apoptosis, respectively.
Figure 7. MiR-886-3p expression levels and function in thyroid cancer cell lines. A) Baseline expression of miR-886-3p in four thyroid
cancer lines. B) Effect of miR-886-3p overexpression on thyroid cancer cell proliferation. Pre-miR-886-3p significantly inhibited thyroid cancer cell
proliferation. Error bars represent standard error of mean. *p#0.001.
doi:10.1371/journal.pone.0024717.g007
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of cells in S phase (12–16%) while decreasing the number of cells
in G0/G1 (11–22%) (p,0.001). We, however, found no significant
increase in the number of cells in apoptosis with and without miR-
886-3p overexpression. This data indicates that miR-886-3p
regulates cell cycle and proliferation consistent with our miR-
886-3p pathway and target prediction analyses.
Because miR-886-3p pathway and target analyses showed genes
regulating focal adhesion were misexpressed, we also determined the
effect of miR-886-3p overexpression on thyroid cancer cell line
spheroid formation and cellular migration. The FTC-133 cell line
forms spheroids when cultured in ultralow adherent culture flasks
within 72 hours. Consistent with the effect of miR-886-3p overexpres-
sion in monolayer cells, we observed a decrease in the number and size
of spheroids in the FTC-133 thyroid cancer cell line which was
sustained for up to 2 weeks in culture (Figure 8). Additionally, miR-
886-3p overexpression decreased the multiple cellular branch-like
structures observed in the negative control cells. We next determined
the effect of miR-886-3p overexpression on cellular migration using the
scratch wound assay. Overexpression of miR-886-3p significantly
inhibited migration of the TPC-1 cell line (p,0.001) (Figure 9).
Discussion
In this study, we performed miRNA profiling of familial and
sporadic papillary thyroid cancer tumor samples. We found four
miRNAs are differentially expressed between these groups, two of
which, miR-886-3p and miR-20a, were validated to be differen-
tially expressed by 3- and 4-fold, respectively. Both of these
miRNAs were downregulated in papillary thyroid cancer as
compared to normal thyroid tissue by 3.5–4-fold. Genome-wide
gene expression pathway and target prediction analyses demon-
strated genes involved in DNA replication and focal adhesion
pathways were targeted by miR-886-3p. Overexpression of miR-
886-3p in thyroid cancer cell lines significantly inhibited cellular
proliferation, the number and size of spheroids, and cellular
migration. Moreover, overexpression of miR-886-3p increased the
number of cells in S phase and decreased the number of cells in
G0G1 phase with no effect on apoptosis.
We are not aware of any other studies which have compared the
miRNA profile of tumors associated with familial cancer
syndromes with their sporadically occurring counterparts. Such
an analysis provides important insights into the genetic pathways
Figure 8. Effect of miR-886-3p overexpression on thyroid cancer cell spheroid formation. Pre-miR-886-3p decreased the size and number
of spheroids in the FTC-133 cell line. A) Representative image of spheroids in culture with miR-886-3p overexpression. B) Quantification of spheroid
difference with miR-886-3p overexpression. The total area occupied by spheroids within an image was measured by circumscribing the perimeter of
each spheroid, marking the entire area, and calculating the pixel numbers by using ImageJ software (Maryland, USA). The experiments were repeated
three times, and similar results were observed. (*** indicates p,0.001).
doi:10.1371/journal.pone.0024717.g008
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important targets of predisposing genetic changes, and, in the
case of FNMTC, the molecular basis. Although most investigators
have suggested that FNMTC is a distinct hereditary syndrome,
arguments against this include that, 1) the same susceptibility
gene(s) and or loci have not been observed across several linkage
studies, 2) nonmalignant thyroid tumors are common and thus a
thyroid cancer diagnosis may be a founder effect or incidentally
discovered, and 3) the expressivity is variable [2]. On the other
hand, several studies support FNMTC as being a distinct
hereditary syndrome because, 1) multiple kindreds have been
reported to have multigenerational occurrence of FNMTC, 2)
there is a higher rate of thyroid cancer in men and children within
FNMTC pedigrees, 3) there is an earlier age of presentation, and
4) there is male-to-male transmission. Lastly, epidemiologic studies
demonstrate that the risk of thyroid cancer in a first-degree relative
of a patient diagnosed with thyroid cancer is 5-fold higher [28].
Given this controversy, we set out to determine if the expression
profiles of familial and sporadic papillary thyroid cancer were
different. A large number of miRNAs were dysregulated in both
familial and sporadic papillary thyroid cancer compared to normal
thyroid tissue. We performed the miRNA profiling in tumor
samples from patients which were matched for age, gender and
TNM cancer stage. Such an approach was used to minimize
confounding factors which could result in different miRNA
expression profile due to different extent of disease, histologic
subtypes of tumor, and differentiation status of tumor
[29,30,31,32,33,34,35]. Therefore, we believe our careful study
design and analysis provide findings which, for the first time,
support a molecular difference in familial and sporadic papillary
thyroid cancer.
Among the differentially expressed miRNAs between familial
and sporadic papillary thyroid cancer, two miRNAs were
validated to be differentially expressed by quantitative RT-PCR.
Both miR-20a (13q31.3) and miR-886-3p (5q31.2) are not located
in chromosomal loci previously identified as susceptibility loci by
linkage studies in kindreds with FNMTC. Given the small
nucleotide lengths of miRNAs, it is not surprising that genetic
alterations in the chromosomal loci encoding miR-20a and miR-
886-3p may have been missed in these studies, even with the use of
high resolution SNP arrays [13]. In the future, germ line sequence
analysis can be used to determine if these miRNAs are candidate
susceptibility genes for FNMTC. Additionally, it will be important
to determine in future studies the mechanism of the general MiR-
886-3p downregulation in thyroid cancer is due to copy number
variation, inactivating mutations or deletion.
We were interested in studying the role of miR-886-3p in
thyroid carcinogenesis for several reasons. Mainly, the function of
miR-886-3p is unknown, the miR-886 gene’s chromosomal
location on 5q31 is shared with transforming growth factor b1,
an important regulator in epithelial carcinogenesis, and the level of
miR-886-3p expression difference between familial and sporadic
papillary thyroid cancer was large (3-fold). Consistent with our
findings, a recent study showed miR-886-3p was downregulated in
squamous cell lung cancer compared with normal lung tissue,
suggesting a potential tumor suppressor role for this miRNA [5].
Using two well-characterized thyroid cancer cell lines with
differing levels of basal miR-866-3p expression, we demonstrated
that miR-886-3p plays a critical role in cellular proliferation and
migration, and regulates genes involved in the DNA replication
and focal adhesion pathways. We selected CDC6, a potent
regulator of DNA replication and oncogenesis [27], for further
analysis and found that CDC6 was a direct target of miR-886-3p.
Although our functional studies were done in thyroid cancer lines,
our data suggests that miR-886-3p is an important regulator of
tumor cell biology in thyroid cancer [26].
Overexpression of miR-886-3p caused dramatic changes in
expression of genes which regulate DNA replication and focal
Figure 9. Overexpression of miR-886-3p inhibited migration of TPC-1 cells. Pre-miR-886-3p significantly decreased cell migration at
22 hours (p,0.001). A) Representative image of wound assay at time 0 and 22 hours after scratch. B) Quantification of wound width closure with
miR-886-3p overexpression. Six different locations were visualized and photographed under a phase-contrast inverted microscope (106
magnification) in each plate at different time points, and three plates were used for each group. The wound width in the 106images was measured
using a standard caliper. The experiments were repeated three times, and similar results were observed. (*** indicates p,0.001).
doi:10.1371/journal.pone.0024717.g009
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knockdown with increased miR-886-3p expression. CDC6 encodes
a protein essential for DNA replication initiation and mitosis, and
thus likely accounts for the increased number of cells in S phase
after overexpression of miR-886-3p [36]. PIP5K1C and PXN are
necessary for cellular adhesion in a variety of cell types [37,38].
ZYX is a phosphoprotein which is concentrated at focal adhesions
and along the actin cytoskeleton and regulates cellular adhesion
and migration [39,40,41,42,43,44]. The effect of these and other
genes in the two pathways identified which are targeted by miR-
886-3p, are consistent with the dramatic effect on cellular
proliferation and migration observed in our miR-886-3p func-
tional studies.
MiR-20a expression has been characterized in several human
malignancies and is dysregulated in prostate, ovarian, head and
neck squamous cell, and colon cancers [34,45,46,47]. In epithelial
cells, miR-20a promotes cellular proliferation and invasion, and
higher expression levels are associated with tumor dedifferentia-
tion [34,48]. Although previous studies of miRNA profiling in
thyroid tumors have not identified miR-20a to be one of the most
dysregulated miRNAs, in our comparison of familial and sporadic
papillary thyroid cancer, it was significantly downregulated in
thyroid cancer [49]. Taken together with its known function as a
growth promoting miRNA and the effects of miR-886-3p, our
findings suggest that these two miRNAs may play a role in the
different clinical feature and tumor biology observed in familial
versus sporadic cases of papillary thyroid cancer [2,6,15].
In summary, our findings suggest that miR-886-3p plays an
important role in thyroid cancer tumor cell biology and may
account for the clinical manifestation of non-medullary thyroid
cancer in sporadic versus familial cases. To our knowledge, this is
the first study to identify a role for miR-886-3p in regulating tumor
cell biology, specifically in thyroid cancer cells.
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